iCAD Inc., a leader in AI-powered breast health solutions, reported financial results for the first quarter ended March 31, 2025. The company achieved a total Annual Recurring Revenue $(ARR)$ of $10.7 million, marking an 18% increase compared to the previous year. Total revenues for the quarter amounted to $4.9 million. The gross profit margin was reported at 86%. In terms of business operations, iCAD successfully closed 92 total deals in Q1, including 19 ProFound Cloud deals. Additionally, the company reported a Non-GAAP Adjusted EBITDA income of $3 thousand for the first quarter of 2025, a notable improvement from a loss of $(1.1) million in the same period of 2024. iCAD stated it has sufficient cash resources, with cash and cash equivalents totaling $20.0 million as of March 31, 2025, to support its planned operations for at least the next 12 months without needing to raise additional funding.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.